Skip to main content

Table 1 Baseline characteristics of included studies

From: To repair or to replace in mitral valve infective endocarditis? an updated meta-analysis

Study

Country

Study type

Total sample size (n)

Mean follow up time (years)

Age (mean(SD))

Sex (female) n (%)

DM n (%)

HTN n (%)

AF n (%)

LVEF (mean (SD))

MVr

MVR

MVr

MVR

MVr

MVR

MVr

MVR

MVr

MVR

MVr

MVR

MVr

MVR

MVr

MVR

Scheggi 2019

Italy

RC

33

57

3

3

63.7(13.1)

63.6 (13.9)

6(18)

20(35)

4(12)

16 (28)

13 (39)

33 (58)

NA

NA

58.5 (9)

60(10.5)

rutman 2005

Austria

RC

34

34

3.14

3.70

51.5(17)

53.2(13.1)

12(35.2)

17(50)

6 (17.6)

6 (17.6)

NA

NA

NA

NA

49 (12)

53(12)

Miura 2014

Japan

RC

36

21

5.3

5.3

57(17)

55(17)

27 (75 )

8 (38 )

6 (17 )

2 (10 )

NA

NA

2 (6 )

2 (10 )

NA

NA

Lee 2018

China

RC

38

33

3.5

3.5

42.3(18.8)

53.7(15.6)

14 (36.8)

13 (39.4)

4 (10.5)

11 (33.3)

NA

NA

NA

NA

70.2(6.8)

69.8(14.5)

Jung 2011

Korea

RC

41

61

4.7

4.7

34.4(16.9)

43.1(14.9)

22(53.6)

28(45.9)

5 (12.2)

8 (13.1)

4 (9.8)

9 (14.8)

NA

NA

64.1(4.2)

62.7(6.2)

Defauw 2020

Netherlands

RC

97

52

5.5

5.5

57 (13)

61 (13)

77(79.3)

30(57.7)

8 (7.9)

13 (25.0)

35 (36.1)

20 (38.4)

18 (18.6)

5 (9.6)

NA

NA

cuerpo 2019

Spain

RC

68

301

1

1

61 (46–70)

63 (53–73)

16(23.5)

90(29.9)

NA

NA

28 (41.2)

148 (49.2)

6 (8.8)

56 (18.6)

NA

NA

helmers 2021

USA

RC

47

47

6.2

6.2

51.3 (13.6)

52.6 (18.0)

16 (34.0)

23 (48.9)

6 (12.8)

7 (14.9)

21 (44.7)

28 (59.6)

NA

NA

58.0 (11.6)

59.3 (12.0)

shang2009

USA

RC

56

33

NA

NA

NA

NA

30(33.7)

NA

17

12

NA

NA

NA

NA

NA

NA

solari 2019

Belgium

RC

155

37

10.20

12.19

60.1 (13.8)

64.6 (11.5)

46(29.7)

19(51.4)

33 (21)

7 (18.9)

NA

NA

NA

NA

NA

NA

tepsuwan 2019

Thailand

RC

38

76

2.76

3.40

44.1 (15.8)

47.5 (15.0)

17(44.7)

21(25)

11

10

NA

NA

NA

NA

58.5 (9)

60(10.5)

tomisc 2018

Netherlands

RC

51

32

3.7

3.7

55 (14)

60 (13)

13 (26)

15 (47)

6 (12)

8 (25)

16 (31)

11 (34)

6 (12)

2 (6)

NA

NA

toyoda2017

USA

RC

367

1603

6.6

6.6

54.9 (15.3)

57.4 (14.6)

124(33.8)

703(43.9)

31 (8.4)

203 (12.7)

175 (47.7)

881 (55.0)

85 (23.2)

405 (25.3)

NA

NA

wang2014

New Zealand

RC

25

35

3.9

3.9

43.1 (16.3)

52.1 (15.7)

11(44)

14(40)

2 (8.0)

3 (8.6)

6 (24.0)

12 (34.3)

2 (8.0)

17 (48.6)

58.0 (11.6)

59.3 (12.0)

Wilhelm 2004

Switzerland

RC

57

97

7

7

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

Mihaljevic 2004

USA

RC

21

32

4

4

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

Sternik 2002

USA

RC

16

28

3.25

3.25

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

yamaguchi 2006

Japan

RC

14

7

NA

NA

55.5 (12)

61 (11)

4(28.6)

4(57.1)

NA

NA

NA

NA

NA

NA

NA

NA

oliver 2022

France

PC

115

37

2.33

2.33

59 (15)

58 (14)

37(32.2)

12(32.4)

15 (13)

9 (24)

NA

NA

13 (11.3)

2 (5.4)

NA

NA

brescia 2021

USA

RC

181

79

3.7

2.7

54 (15)

54 (14)

53 (29)

35 (44)

28 (15)

25 (32)

71 (39)

46 (58)

NA

NA

56 ( 11)

61 (9)

Musci 2010

Germany

RC

32

17

3.59

3.59

44.3 (11)

44.3 (11)

20

10

NA

NA

NA

NA

NA

NA

NA

NA

Gammie 2005

USA

RC

1965

4662

9

9

56

67

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

LEE 2024

Taiwan

RC

467

467

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

  1. RC; retrospective cohort, PC; prospective cohort, MVr; mitral valve repair, MVR; mitral valve replacement. DM; diabetes milletus, HTN; hypertension, AF; atrial fibrillation, LVEF; left ventricular ejection fraction; SD; standard deviation; N; number of patients, NA; not available